Clinical Trial Update: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating maintenance therapy with tislelizumab and metronomic capecitabine in high-risk locoregionally-advanced nasopharyngeal carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING